ADMA Biologics, Inc. Aktie News

ADMA Biologics' earnings are surging due to higher plasma yield and a profitable shift toward premium IG brands, boosting margins. FDA approval of yield-enhancement technology increases finished IG output by 20%, driving efficiency and supporting ongoing revenue and margin growth. Expanded plasma sourcing and improved logistics de-risk supply, supporting long-term growth and simplifying distrib...

ADMA's growth remains centered on Asceniv, Bivigam, and NABI-HB. These are its main value drivers today. ADMA Biologics' recent Q2 report showed that the company is working on enhancing its plasma yields by over 20% in IG output. This should help them with margin expansion beginning in 2026. ADMA also reaffirmed its guidance for over $500 million in 2025 revenues and over $625 million by 2026. ...

ADMA Biologics experienced a significant stock pullback on Thursday after Q2 results, presenting a potential buying opportunity for investors. The company now operates 10 plasma collection centers and manufactures key products BIVIGAM and ASCENIV, supporting its solid growth outlook. The company recently announced a $500 million stock buyback program and initiated a new manufacturing process th...

Adma Biologics (ADMA) Q2 Revenue Up 14%

ADMA Biologics, Inc. (NASDAQ:ADMA ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Adam S. Grossman - Co-Founder, President, CEO & Director Brad Tade - CFO & Treasurer Skyler Bloom - Senior Director of Business Development & Corporate Strategy Conference Call Participants Anthony Charles Petrone - Mizuho Securities USA LLC, Research Division Gary Jay Nachman - R...

2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item

RAMSEY, N.J. and BOCA RATON, Fla.

ADMA's revenue growth has plateaued over the last three quarters, raising concerns about near-term momentum and justifying a shift to a neutral stance. Despite strong fundamentals and a promising long-term outlook, recent earnings misses and weak sequential sales make the current risk/reward profile less attractive. Given limited upside and better opportunities elsewhere, I have taken profits a...